-
Aarti Drugs Analyst Review 2027: Record Quarter, Profit Up 83% and a P/E Half the Industry’s
- November 17, 2026
- Posted by: Chaitanya Auti
- Category: Market
No Comments
Aarti Drugs posted its highest-ever quarterly revenue, EBITDA and profit in Q2 FY27, with profit up 83% on better API pricing. It still trades at about 20 times earnings. We cover the business, margins, volume gap and 2027 triggers.
-
3 Small-Cap API and Generics Stocks With a Strong Future Roadmap: SMS Pharmaceuticals, Aarti Drugs and Senores Pharmaceuticals
- October 7, 2026
- Posted by: Ankit Jaiswal
- Category: Best Stocks
SMS Pharmaceuticals, Aarti Drugs and Senores Pharmaceuticals compared on growth, margins, debt and valuation, with the roadmap and risks investors should track.